Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Kuno T, Watanabe A, Shoji S, Fujisaki T, Ueyama H, Takagi H, Deharo P, Cuisset T, Bangalore S, Mehran R, Stone GW, Kohsaka S, Bhatt DL.
Circ Cardiovasc Interv. 2023 Sep;16(9):e013242. doi: 10.1161/CIRCINTERVENTIONS.123.013242. Epub 2023 Aug 23.
Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study.
Ali ZA, Nef H, Escaned J, Werner N, Banning AP, Hill JM, De Bruyne B, Montorfano M, Lefevre T, Stone GW, Crowley A, Matsumura M, Maehara A, Lansky AJ, Fajadet J, Di Mario C.
Circ Cardiovasc Interv. 2019 Oct;12(10):e008434. doi: 10.1161/CIRCINTERVENTIONS.119.008434. Epub 2019 Sep 25.
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
Valgimigli M, Wlodarczak A, Tölg R, Merkely B, Kelbæk H, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Honton B, Dietrich PL, Stammen F, Ferdinande B, Silvain J, Capodanno D, Cayla G; Bioflow-DAPT Investigators.
Circulation. 2023 Sep 26;148(13):989-999. doi: 10.1161/CIRCULATIONAHA.123.065448. Epub 2023 Aug 25.
Dual antiplatelet therapy after coronary drug-eluting stent implantation in China: A large single center study.
Xu JJ, Gao Z, Zhang Y, Gao LJ, Chen J, Qiao SB, Gao RL, Yang YJ, Xu B, Yuan JQ.
Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):566-572. doi: 10.1002/ccd.27500. Epub 2018 Jan 23.
First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT.
Saito S, Bennett J, Nef HM, Webster M, Namiki A, Takahashi A, Kakuta T, Yamazaki S, Shibata Y, Scott D, Vrolix M, Menon M, Möllmann H, Werner N, Neylon A, Mehmedbegovic Z, Smits PC, Morice MC, Verheye S; BIOADAPTOR-RCT Collaborators.
EClinicalMedicine. 2023 Oct 24;65:102304. doi: 10.1016/j.eclinm.2023.102304. eCollection 2023 Nov.
Feasibility and Clinical Outcomes of 48 mm Drug-Eluting Stents in the Management of Patients With Coronary Artery Disease.
El Amrawy AM, Loutfi MI, El Tahan SM, Ayad SW.
J Invasive Cardiol. 2021 Dec;33(12):E960-E967. doi: 10.25270/jic/20.00660. Epub 2021 Nov 24.
Five-year clinical outcomes of a 2.25 mm sirolimus-eluting stent in Japanese patients with very small coronary artery disease: final results of the CENTURY JSV study.
Shishido K, Ando K, Ito Y, Takamisawa I, Yajima J, Kimura T, Kadota K, Saito S.
Cardiovasc Interv Ther. 2023 Apr;38(2):194-201. doi: 10.1007/s12928-022-00890-y. Epub 2022 Sep 2.
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.
Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Alfonso Jiménez Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB; PIONEER III Trial Investigators.
Circulation. 2021 Jun;143(22):2143-2154. doi: 10.1161/CIRCULATIONAHA.120.052482. Epub 2021 Apr 6.
Pathobiology of stent thrombosis after drug-eluting stent implantation.
Vorpahl M, Yazdani SK, Nakano M, Ladich E, Kolodgie FD, Finn AV, Virmani R.
Curr Pharm Des. 2010;16(36):4064-71. doi: 10.2174/138161210794454879.
Drug-coated balloon in the treatment of coronary bifurcation lesions: A hope or hype?
Dash D, Mody R, Ahmed N, Malan SR, Mody B.
Indian Heart J. 2022 Nov-Dec;74(6):450-457. doi: 10.1016/j.ihj.2022.10.193. Epub 2022 Nov 5.
